WallStSmart

Masco Corporation (MAS)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 59% more annual revenue ($12.22B vs $7.68B). VRTX leads profitability with a 35.5% profit margin vs 10.9%. VRTX appears more attractively valued with a PEG of 1.69. VRTX earns a higher WallStSmart Score of 68/100 (B-).

MAS

Strong Buy

67

out of 100

Grade: B-

Growth: 5.3Profit: 8.5Value: 5.0Quality: 7.5
Piotroski: 4/9Altman Z: 2.35

VRTX

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.61
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MAS.

VRTXUndervalued (+52.4%)

Margin of Safety

+52.4%

Fair Value

$949.55

Current Price

$446.83

$502.72 discount

UndervaluedFair: $949.55Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MAS3 strengths · Avg: 9.3/10
Return on EquityProfitability
84.6%10/10

Every $100 of equity generates 85 in profit

Debt/EquityHealth
-13.6410/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
20.0%8/10

Earnings expanding 20.0% YoY

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6110/10

Safe zone — low bankruptcy risk

Market CapQuality
$114.33B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

MAS2 concerns · Avg: 3.0/10
PEG RatioValuation
1.874/10

Expensive relative to growth rate

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

P/E RatioValuation
26.7x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MAS

The strongest argument for MAS centers on Return on Equity, Debt/Equity, EPS Growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : MAS

The primary concerns for MAS are PEG Ratio, Free Cash Flow.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

MAS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

MAS carries more volatility with a beta of 1.31 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (68/100 vs 67/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Masco Corporation

INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA

Masco Corporation is a manufacturer of products for the home improvement and new home construction markets.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?